Rejuve Therapeutics, based in Rockville, Maryland, USA, was founded in 2021 to pioneer cutting-edge research and development of solutions aimed at understanding, slowing, and ultimately reversing the aging process.
At Rejuve Therapeutics, we believe that aging is not an inevitable fate. Rather, we see it as a programmed biological process—carefully orchestrated by nature to support the survival of the species as a whole.
This belief is supported by the fact that humans and other animals can naturally rejuvenate themselves during reproduction, by reprogramming cells derived from the parents back to an age-zero state—a principle further validated by advances in animal cloning studies.
Leveraging the power of artificial intelligence and bioinformatics, together with our unique strategies and proprietary rejuvenation screening platform, we are dedicated to identifying the key genes capable of rejuvenating cells in the human body, replicating the natural rejuvenation that occurs during reproduction.
Through our innovative approaches, we strive to develop transformative methods and solutions that halt and reverse aging at its root—extending human lifespan while promoting long-term health, vitality, and active living.
Dr. Gordon Ma is a pioneering scientist with a distinguished career in medical genetics, epigenetics, and regenerative medicine. His groundbreaking research has shaped our understanding of epigenetics in aging and early cancer formation. His postdoctoral work at Harvard Medical School and NIH advanced studies in non-coding RNA during embryo development, embryonic stem cell differentiation and its application in cardiovascular regenerative medicine. As a scientist and entrepreneur, Dr. Ma has led multiple biotech ventures, striving to translate research into transformative therapies. Passionate about aging and rejuvenation, he co-foundered Rejuve Therapeutics to explore the mechanisms of cellular senescence and rejuvenation. His team recently discovered a gene cocktail capable of rejuvenating human arterial endothelial cells while preserving their identity. With relentless dedication to longevity science, Dr. Ma is aiming to develop innovative solutions for promoting longevity and healthy aging. Dr. Ma’s expertise, leadership, and scientific vision position him at the forefront of rejuvenation research.
Dr. Aibing Wang is a distinguished biomedical scientist with over 23 years of experience in molecular biology, cell biology, oncology, and vaccine development. He earned his Ph.D. in Biochemistry and Molecular Biology from Peking Union Medical College and has made significant contributions in both academia and industry. As a former Research Assistant Professor at Georgetown University, Dr. Wang focused on cancer development and drug discovery, pioneering research on TERT’s role in tumorigenesis and screening novel therapeutics for cervical cancer. His expertise extends to developing lipid nanoparticle-based targeted therapies for brain tumors and conducting extensive in vivo studies. With 84 publications, five patents, and three NIH awards, his work has had a lasting impact on biomedical innovation. At Rejuve Therapeutics, with extensive experience in molecular biology, cell biology, oncology, and vaccine development, Dr. Wang focus on the development of packaging and delivery solutions of our new rejuvenation gene cocktails for in vitro and in vivo studies
Dr. Dazhi Lai is a highly accomplished scientist and entrepreneur with expertise in immunology, regenerative medicine, aging, biotechnology, and drug development. He earned his Ph.D. in Biotechnology from the Academy of Military Medical Sciences and completed postdoctoral training at Yale University. His research has spanned virology, immunology, aging, and therapeutic development, leading to significant discoveries, including calcium signaling in innate immunity and transcriptional regulation of immune responses. Dr. Lai has also spearheaded the development of innovative recombinant proteins and monoclonal antibodies for drug discovery. His leadership in translational research has resulted in multiple patents and FDA-approved therapeutics. Passionate about bridging scientific discovery with clinical application, he continues to push the boundaries of biomedical innovation. At Rejuve Therapeutics, Dr. Lai’s leadership and scientific expertise in immunology and regenerative medicine continue to drive innovation in the area of aging and rejuvenation in human immune system.
